Alitretinoin

Retinoid

DB00523

Approved Indication

For topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.

9 Targets

0 Resistance Mutations

0 References

5UAN Structure Loaded

3D Structure PDB: 5UAN

Switch structure: RCSB ↗

Protein Targets

RARA P10276 ✓ RARB P10826 ✓ 1 PDB RARG P13631 ✓ 2 PDB RXRA P19793 ✓ 13 PDB RXRB P28702 ✓ RXRG P48443 ✓ CYP26C1 Q6V0L0 IGFBP3 P17936 PSG5 Q15238

Mechanism of Action

Alitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells.

Details

DrugBank ID DB00523 ↗

Approval Date 1999-02-03

Molecular Weight 300.4351 g/mol

Drug Class Retinoid

ATC Codes D11AH04, L01XX22

Synonyms (7E,9Z,11E,13E)-retinoic acid, 9-cis-retinoic acid, 9-cis-Tretinoin

PubChem CID: 449171 ↗

ChEMBL CHEMBL705 ↗

SMILES

C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O

ADMET Profile

Computing properties…